Composition comprising a lipophilic organic UV-screening agent, a gemini surfactant and at least 8% by weight of a c 1-c 4 monoalcohol

Abstract

The present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising at least one lipophilic organic UV-screening agent, at least one suitably selected gemini surfactant, and at least one C1-C4 monoalcohol in an amount at least equal to 8% by weight of the total weight of the composition, and to the use of said composition in the cosmetic and dermatological fields, in particular for caring for and treating keratin materials, and in particular for caring for, protecting and / or making up the skin of the body or of the face.

Description

Composition comprising a lipophilic organic UV-screening agent, a gemini surfactant and at least 8% by weight of a C1-C4monoalcohol

[0001] The present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising at least one lipophilic organic UV-screening agent, at least one suitably selected gemini surfactant, and at least one C1-C4monoalcohol in an amount at least equal to 8% by weight of the total weight of the composition, and to the use of said composition in the cosmetic and dermatological fields, in particular for caring for and treating keratin materials, and in particular for caring for, protecting and / or making up the skin of the body or of the face.

[0002] It is known that light radiation with a wavelength of between 280 nm and 400 nm enables darkening of the human epidermis. Rays with a wavelength more particularly between 280 and 320 nm, known as UVB rays, cause skin erythema and burns which can be detrimental to the development of a natural tan.

[0003] For these reasons, and also for esthetic reasons, there is a constant demand for means for controlling this natural tanning in order thus to control the color of the skin: UVB radiation should thus be screened out. It is also known that UVA rays, with wavelengths of between 320 and 400 nm, which cause darkening of the skin, are capable of bringing about a detrimental change in the latter, in particular in the case of sensitive skin or of skin continually exposed to solar radiation. UVA rays cause in particular a loss in the elasticity of the skin and the appearance of wrinkles, resulting in premature skin aging.

[0004] Thus, for esthetic and cosmetic reasons, such as maintaining the natural elasticity of the skin for example, more and more people wish to control the effect of UVA rays on their skin. It is therefore desirable also to screen out UVA radiation.

[0005] For the purpose of protecting the skin and keratin materials against UV radiation, photoprotective compositions comprising organic screening agents that are active in the UVA range and in the UVB range are generally used.

[0006] Many cosmetic compositions intended for photoprotection of the skin have been proposed to date. These compositions generally contain, in an emulsified liquid support (preferably an oil-in-water emulsion), one or more organic molecules, capable of absorbing ultraviolet radiation, which are soluble in the oily and / or aqueous phase. The use of mineral pigments of a metal oxide, such as titanium dioxide, in such anti-sun compositions is increasingly frequent since these particles, which are invisible to the naked eye due to their small size, make it possible to increase the protection factor of the compositions containing same.

[0007] One of the major drawbacks of these photoprotective emulsions containing organic screening agents and / or mineral screening agents lies in the difficulty in reconciling good product stability, easy product application, effective protection, and a good cosmetic quality such as a fresh, non-tacky feel.

[0008] This is particularly the case when the anti-sun composition comprises lipophilic organic UV-screening agents, and in particular when these lipophilic organic UV-screening agents are solid at room temperature.

[0009] The applicant has discovered that the combination of a gemini surfactant and at least 8% by weight of at least one C1-C4monoalcohol makes it possible to improve the stability of compositions comprising at least one lipophilic organic UV-screening agent, and in particular the stability of the compositions comprising solid lipophilic organic UV-screening agents, while allowing effective protection against ultraviolet rays and good cosmetic qualities. It also enables the anti-sun composition to exhibit less adhesion to sand, and considerably improves the hydration of the skin, both upon application of the sunscreen composition and over time after application.

[0010] Thus, according to a first aspect, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition.

[0011] According to a particular embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;the composition being free of ethylhexyl methoxycinnamate (octinoxate).

[0012] According to another particular embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;the composition being free of ethylhexyl salicylate.

[0013] According to a preferred embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;the composition being free of ethylhexyl methoxycinnamate (octinoxate) and ethylhexyl salicylate.

[0014] According to another preferred embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;the composition being free of liquid lipophilic organic UV-screening agent.

[0015] According to another particular embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one solid lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition.

[0016] According to a preferred embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;wherein the lipophilic organic UV-screening agent(s) present in the composition are solids.

[0017] According to another preferred embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one solid lipophilic organic UV-screening agent other than butyl methoxydibenzoylmethane;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition.

[0018] According to another preferred embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one solid lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;the composition being free of liquid lipophilic organic UV-screening agents.

[0019] According to another particular embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one solid lipophilic organic UVA screening agent and at least one solid lipophilic organic UVB screening agent;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition.

[0020] According to another particular embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one solid lipophilic organic hybrid UV-screening agent capable of absorbing UVA and UVB rays;- at least one gemini surfactant as defined below; and- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition.

[0021] According to another embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below;- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;- at least one semicrystalline polymer containing at least one alkyl acrylate chain, the alkyl radicals preferably being C16-C22radicals ;the composition being free of liquid lipophilic organic UV-screening agent.

[0022] According to another embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below;- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition ;- at least one semicrystalline polymer containing at least one alkyl acrylate chain, the alkyl radicals preferably being C16-C22radicals ;wherein the lipophilic organic UV-screening agent(s) present in the composition are solids.

[0023] According to another embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below;- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;- at least one carboxylic or carboxylate anionic surfactant chosen from amino acids modified with at least one C8-C30, preferably C10-C24, and even more preferentially C16-C22, hydrocarbon chain, and salts thereof ;the composition being free of liquid lipophilic organic UV-screening agent.

[0024] According to another embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below;- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition ;- at least one carboxylic or carboxylate anionic surfactant chosen from amino acids modified with at least one C8-C30, preferably C10-C24, and even more preferentially C16-C22, hydrocarbon chain, and salts thereof ;wherein the lipophilic organic UV-screening agent(s) present in the composition are solids.

[0025] According to another embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below;- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition;- at least one semicrystalline polymer containing at least one alkyl acrylate chain, the alkyl radicals preferably being C16-C22radicals ;- at least one carboxylic or carboxylate anionic surfactant chosen from amino acids modified with at least one C8-C30, preferably C10-C24, and even more preferentially C16-C22, hydrocarbon chain, and salts thereof ;the composition being free of liquid lipophilic organic UV-screening agent.

[0026] According to another embodiment, the present invention relates to a composition, in particular a cosmetic or dermatological composition, comprising:- at least one lipophilic organic UV-screening agent;- at least one gemini surfactant as defined below;- at least one C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition ;- at least one semicrystalline polymer containing at least one alkyl acrylate chain, the alkyl radicals preferably being C16-C22radicals ;- at least one carboxylic or carboxylate anionic surfactant chosen from amino acids modified with at least one C8-C30, preferably C10-C24, and even more preferentially C16-C22, hydrocarbon chain, and salts thereof ;wherein the lipophilic organic UV-screening agent(s) present in the composition are solids.

[0027] Against all expectations, the inventors have found that the use, in a photoprotective composition comprising lipophilic organic UV-screening agent(s), of the combination of a suitably selected gemini surfactant with a C1-C4monoalcohol in an amount at least equal to 8% by weight relative to the total weight of the composition, makes it possible to obtain a composition which has a significantly reduced adhesion to sand. Furthermore, in presence of a semicrystalline polymer containing at least one alkyl acrylate chain, the composition considerably improves the hydration of the skin, both upon application of the sunscreen composition and over time after application. And in presence of a carboxylic or carboxylate anionic surfactant chosen from amino acids modified with at least one C8-C30, the composition has a better stability over time and at different temperature.

[0028] Furthermore, the compositions according to the invention are easy to spread, have a high photoprotective power and also have good cosmetic properties, such as a refreshing capacity and a non-greasy and non-tacky texture.

[0029] According to another of its aspects, the invention also relates to the use of a composition as defined above for caring for keratin materials, in particular the skin of the body or of the face.

[0030] According to yet another of its aspects, the invention also relates to a non-therapeutic cosmetic method for making up and / or caring for keratin materials, in particular the skin of the body or of the face, comprising at least the application of a cosmetic composition as defined previously to said keratin materials.

[0031] The invention also relates to a non-therapeutic cosmetic method for limiting the darkening of the skin and / or improving the color and / or uniformity of the complexion, comprising the application of at least one cosmetic composition as defined previously to the surface of the keratin material.

[0032] The invention also relates to a non-therapeutic cosmetic method for preventing and / or treating the signs of aging of a keratin material, comprising the application of at least one cosmetic composition as defined previously to the surface of the keratin material.

[0033] The composition in accordance with the invention exhibits good stability. This stability can be evaluated macroscopically and / or microscopically, after storage for 24 hours, one week, one month, or two months, at room temperature (25°C), at 4°C, at 45°C or at 55°C. A stable composition generally maintains its pleasantness and its sensory signature on application over time. More specifically, the stability of a composition can be evaluated qualitatively for example by the absence of any phase-separation phenomenon or appearance of crystals, or quantitatively through the monitoring of the change in parameters such as the viscosity or the pH.

[0034] The composition in accordance with the invention exhibits low adhesion to sand. The adhesion to sand can be evaluated in vitro according to a protocol such as the one detailed in the examples, based on the measurement of the amount of sand remaining bonded by the composition to a well-defined support.

[0035] The composition according to the invention also makes it possible to considerably improve the hydration of the skin, both upon application of the sunscreen composition and over time after application. Skin hydration can be determined in vivo by corneometry measurements, according to a protocol such as the one detailed in the examples.

[0036] In the context of the invention, the screening efficiency is evaluated from the evaluation of SPF and UVAPF.

[0037] For the purposes of the present invention, the term “SPF” means the sun protection factor, which measures the level of protection against UVB rays. The SPF value corresponds to the ratio between the minimum time it takes to obtain a sunburn with a photoprotective composition and the minimum time it takes without a product. More specifically, the “SPF” is defined in the articleA new substrate to measure sunscreen protection factors throughout the ultraviolet spectrum, J. Soc. Cosmet. Chem., 40, 127-133 (May / June 1989).

[0038] The SPF (sun protection factor) may be evaluatedin vitrousing the Labsphere® spectrophotometer. The plate is the material to which the photoprotective composition is applied. For this protocol, poly(methyl methacrylate) (PMMA) plates have proved to be ideal. A particular protocol, presented as an example, is currently being approved by ISO under the name ISO Committee Draft 23675.

[0039] The evaluation of the sun protection factor (SPF) of the compositions can also be performed in vivo according to the ISO 24444: 2019 protocol “Cosmetics - Sun protection test methods - In vivo determination of the sun protection factor (SPF)”.

[0040] For the purposes of the present invention, the term “UVAPF” is understood to mean the index characterizing the protection against UVA rays. In particular, this index can be measured in vivo according to the “PPD” (Persistent Pigment Darkening) method, ISO-24442: 2022 protocol, by skin color observed 2 to 4 hours after exposure to UVA rays. The protection against UVA rays can also be evaluated in vitro using the Labsphere® spectrophotometer. The plate is the material to which the anti-sun composition is applied. For this protocol, poly(methyl methacrylate) (PMMA) plates have proved to be ideal. The ISO 24443: 2021 protocol describes such an in vitro method.

[0041] Other characteristics, aspects and advantages of the invention will become apparent on reading the detailed description that follows.

[0042] The composition according to the invention is intended for topical application and thus contains a physiologically acceptable medium. The term “physiologically acceptable medium” means here a medium that is compatible with keratin materials.

[0043] In the context of the present invention, the term “keratin material” notably means the skin, scalp, keratin fibers, such as the eyelashes, eyebrows, head hair and body hair, nails, mucous membranes, such as the lips, and more particularly the skin and mucous membranes (body, face, area around the eyes, eyelids, lips, preferably body, face and lips).

[0044] In the text hereinbelow, unless otherwise indicated, the limits of a range of values are included in that range, notably in the expressions “between” and “ranging from ... to ...”.

[0045] Moreover, the expressions “at least one” and “at least” used in the present description are equivalent respectively to the expressions “one or more” and “greater than or equal to”.

[0046] According to the invention, the term “preventing” or “prevention” means reducing the risk of occurrence or slowing down the occurrence of a given phenomenon, namely, according to the present invention, the signs of aging of a keratin material.

[0047] For the purposes of the present invention, a “liquid lipophilic organic UV-screening agent” is understood to mean a lipophilic organic UV-screening agent which, at room temperature (25°C) and atmospheric pressure (760 mmHg), flows under its own weight.

[0048] For the purposes of the present invention, a “solid lipophilic organic UV-screening agent” is understood to mean a lipophilic organic UV-screening agent which, at room temperature (25°C) and atmospheric pressure (760 mmHg), does not flow under its own weight, in other words is not liquid; the solid lipophilic organic UV-screening agent may or may not be malleable. It may in particular be in powder form.

[0049] An “organic UVA screening agent” is understood to mean any organic chemical molecule capable of absorbing exclusively UVA radiation in the wavelength range between 320 and 400 nm.

[0050] An “organic UVB screening agent” is understood to mean any organic chemical molecule capable of absorbing exclusively UVB radiation in the wavelength range between 280 and 320 nm.

[0051] A “hybrid organic UV-screening agent” is understood to mean any organic chemical molecule capable of absorbing UVA radiation in the wavelength range between 320 and 400 nm, but also UVB radiation in the wavelength range between 280 and 320 nm.

[0052] A “lipophilic organic UV-screening agent” is understood to mean any cosmetic or dermatological organic compound for screening out UV radiation, which can be fully dissolved in molecular form in a liquid fatty phase or else which can be solubilized in colloidal form (for example in micellar form) in a liquid fatty phase.

[0053] For the purposes of the present invention, a “hydrophilic organic UV-screening agent” is understood to mean a water-soluble organic UV-screening agent or a water-dispersible organic UV-screening agent.

[0054] A “water-soluble organic screening agent” is understood to mean any cosmetic or dermatological organic compound for screening out UV radiation, which can be fully dissolved in molecular form in a liquid aqueous phase or else which can be solubilized in colloidal form (for example in micellar form) in a liquid aqueous phase.

[0055] A “water-dispersible organic screening agent” is understood to mean any cosmetic or dermatological organic compound for screening out UV radiation that is capable of forming, in a liquid aqueous phase, a homogeneous suspension of particles with a volume-average size of less than 100 microns. The volume-average size is determined by laser diffraction particle size analysis.

[0056] An “insoluble UV-screening agent” is understood to mean any cosmetic or dermatological organic or inorganic compound for screening out UV radiation which has a solubility in water of less than 0.5% by weight and a solubility of less than 0.5% by weight in the majority of organic solvents such as liquid paraffin, fatty alcohol benzoates and fatty acid triglycerides, for example Miglyol 812® sold by Dynamit Nobel. This solubility, determined at 70°C, is defined as the amount of product in solution in the solvent at equilibrium with an excess of solid in suspension after returning to room temperature. It can be easily evaluated in the laboratory.UV-screening agents

[0057] The compositions according to the invention contain one or more lipophilic organic UV-screening agents.

[0058] The composition may also comprise at least one additional UV-screening agent chosen from hydrophilic organic UV-screening agents, insoluble organic or inorganic UV-screening agents and mineral pigments. Preferentially, the screening system will be constituted of organic UV-screening agents, in particular hydrophilic, lipophilic or insoluble organic UV-screening agents, and preferably hydrophilic organic UV-screening agents and lipophilic organic UV-screening agents.Lipophilic organic UV-screening agents

[0059] The lipophilic organic screening agents are notably chosen from cinnamic compounds; anthranilate compounds; salicylic compounds; dibenzoylmethane compounds; benzylidene camphor compounds; benzophenone compounds; β,β-diphenylacrylate compounds; triazine compounds; benzotriazole compounds; benzalmalonate compounds, in particular those cited in patent US 5624663; benzimidazole derivatives; imidazoline compounds; bis-benzazolyl compounds, as described in patents EP 669 323 and US 2,463,264; methylene bis(hydroxyphenylbenzotriazole) compounds, as described in patent applications US 5,237,071, US 5,166,355, GB 2303549, DE 197 26 184 and EP 893 119; benzoxazole compounds, as described in patent applications EP 0 832 642, EP 1 027 883, EP 1 300 137 and DE 101 62 844; screening polymers and screening silicones, such as those described notably in patent application WO 93 / 04665; dimeric α-alkylstyrene derivatives, such as those described in patent application DE  198 55 649; 4,4-diarylbutadiene compounds, as described in patent applications EP 0 967 200, DE 197 46 654, DE 197 55 649, EP-A-1 008 586, EP 1 133 980 and EP 133 981, and mixtures thereof.

[0060] Preferably, the lipophilic organic screening agent(s) are chosen from salicylic compounds, dibenzoylmethane compounds, benzylidene camphor compounds; benzophenone compounds; triazine compounds; benzotriazole compounds; and mixtures thereof.

[0061] As examples of lipophilic organic photoprotective agents, mention may be made of those denoted hereinbelow under their INCI name and / or their chemical name.

[0062] Cinnamic compounds:ethylhexyl methoxycinnamate sold in particular under the trade name PARSOL® MCX by DSM Nutritional Products;isoamyl p-methoxycinnamate sold under the trade name NEO HELIOPAN E 1000® by Symrise,

[0063] Dibenzoylmethane compounds:butyl methoxydibenzoylmethane notably sold under the trade name PARSOL® 1789 by DSM Nutritional Products,

[0064] Salicylic compounds:homosalate sold under the name Parsol® HMS by DSM Nutritional Products,ethylhexyl salicylate sold under the name NEO HELIOPAN® OS by Symrise,

[0065] β,β-Diphenylacrylate compounds:octocrylene, notably sold under the trade name UVINUL® N 539 T by BASF,

[0066] Benzophenone compounds:benzophenone-3 or oxybenzone, sold under the trade name UVINUL® M 40 by BASF,diethylamino hydroxybenzoyl hexyl benzoate sold under the trade name UVINUL® A Plus by BASF,

[0067] Benzylidene camphor compounds:4-methylbenzylidene camphor sold under the name EUSOLEX® 6300 by Merck,

[0068] Phenylbenzotriazole compounds:drometrizole trisiloxane manufactured under the name MEXORYL® XL by Noveal,

[0069] Methylene bis(hydroxyphenylbenzotriazole) compounds:methylene bis-benzotriazolyl tetramethylbutylphenol, in particular in solid form, such as the product sold under the trade name MIXXIM BB / 100® by Fairmount Chemical,

[0070] Triazine compounds:- 3,3’-(1,4-phenylene)bis(5,6-diphenyl-1,2,4-triazine), with the INCI name Phenylene Bis-Diphenyltriazine,- bis-ethylhexyloxyphenol methoxyphenyl triazine sold under the trade name TINOSORB® S by BASF,- ethylhexyl triazone sold in particular under the trade name UVINUL® T 150 by BASF,- diethylhexyl butamido triazone sold under the trade name UVASORB® HEB by 3V Sigma,- symmetrical triazine screening agents substituted with naphthalenyl groups or polyphenyl groups described in patent US 6,225,467, patent application WO 2004 / 085412 (see compounds 6 and 9) or the document “Symmetrical Triazine Derivatives” IP.COM IPCOM000031257 Journal, INC WEST HENRIETTA, NY, US (20 September 2004),

[0071] Anthranilic compounds:menthyl anthranilate sold under the trade name NEO HELIOPAN® MA by Symrise,

[0072] Benzalmalonate compounds:polyorganosiloxane comprising benzalmalonate functions, such as polysilicone-15, sold under the trade name PARSOL SLX® by Hoffmann-La Roche.

[0073] According to a particular embodiment, the composition in accordance with the invention is free of ethylhexyl methoxycinnamate (octinoxate). For the purposes of the present invention, the expression “free of ethylhexyl methoxycinnamate” is understood to mean an amount of ethylhexyl methoxycinnamate of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not contain any ethylhexyl methoxycinnamate.

[0074] According to a particular embodiment, the composition in accordance with the invention is free of octocrylene. For the purposes of the present invention, the expression “free of octocrylene” is understood to mean an amount of octocrylene of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not contain any octocrylene.

[0075] According to a preferred embodiment, the composition in accordance with the invention is free of ethylhexyl methoxycinnamate and / or octocrylene. For the purposes of the present invention, the expression “free of ethylhexyl methoxycinnamate and / or octocrylene” is understood to mean a total amount of ethylhexyl methoxycinnamate and octocrylene of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not contain any ethylhexyl methoxycinnamate or any octocrylene.

[0076] According to a particular embodiment, the composition in accordance with the invention is free of ethylhexyl salicylate. For the purposes of the present invention, the expression “free of ethylhexyl salicylate” is understood to mean an amount of ethylhexyl salicylate of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not contain any ethylhexyl salicylate.

[0077] According to a preferred embodiment, the composition in accordance with the invention is free of ethylhexyl methoxycinnamate and / or ethylhexyl salicylate. For the purposes of the present invention, the expression “free of ethylhexyl methoxycinnamate and / or ethylhexyl salicylate” is understood to mean a total amount of ethylhexyl methoxycinnamate and ethylhexyl salicylate of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not contain any ethylhexyl methoxycinnamate or any ethylhexyl salicylate.

[0078] According to a more preferred embodiment, the composition in accordance with the invention is free of ethylhexyl methoxycinnamate and / or octocrylene and / or ethylhexyl salicylate and / or homosalate. For the purposes of the present invention, the expression “free of ethylhexyl methoxycinnamate and / or octocrylene and / or ethylhexyl salicylate and / or homosalate” is understood to mean a total amount of ethylhexyl methoxycinnamate, octocrylene, ethylhexyl salicylate and homosalate of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not contain any ethylhexyl methoxycinnamate or any octocrylene or any ethylhexyl salicylate or any homosalate.

[0079] According to an even more preferred embodiment, the composition in accordance with the invention is free of liquid lipophilic organic UV-screening agents. For the purposes of the present invention, the expression “free of liquid lipophilic organic UV-screening agents” is understood to mean a total amount of liquid lipophilic organic UV-screening agents of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not contain any liquid lipophilic organic UV-screening agents.

[0080] According to another particular embodiment of the invention, the composition comprises at least one solid lipophilic organic UV-screening agent.

[0081] According to a preferred embodiment, the composition comprises at least one solid lipophilic organic UV-screening agent other than butyl methoxydibenzoylmethane. The composition may then comprise butyl methoxydibenzoylmethane or may not comprise butyl methoxydibenzoylmethane.

[0082] According to a preferred embodiment, the amount of solid lipophilic organic UV-screening agents is greater than or equal to 10% by weight, preferably greater than or equal to 25% by weight, notably greater than or equal to 55% by weight, and even more preferentially greater than or equal to 80% by weight of the total weight of lipophilic organic screening agents present in the composition.

[0083] Preferably, all the lipophilic organic UV-screening agents present in the composition are solids.

[0084] Examples of solid lipophilic organic UV-screening agents which may be mentioned are: butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, 4-methylbenzylidene camphor, drometrizole trisiloxane, phenylene bis-diphenyltriazine, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, diethylhexyl butamido triazone, preferably butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, drometrizole trisiloxane, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, and even more preferentially butyl methoxydibenzoylmethane, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone.

[0085] According to a particular embodiment of the invention, the composition comprises at least one solid lipophilic organic UVA-screening agent, preferably chosen from butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, and at least one solid lipophilic organic UVB-screening agent, preferably chosen from ethylhexyl triazone and diethylhexyl butamido triazone.

[0086] According to another particular embodiment of the invention, the composition comprises at least one solid lipophilic organic hybrid UV-screening agent capable of absorbing UVA and UVB rays, preferably chosen from drometrizole trisiloxane and bis-ethylhexyloxyphenol methoxyphenyl triazine.

[0087] The amount of lipophilic organic UV-screening agents in the composition in accordance with the invention is between 5% and 25% by weight, preferably between 8% and 20% by weight, and even more preferentially between 10% and 18% by weight of the total weight of the composition.Hydrophilic organic UV-screening agents

[0088] The composition according to the invention may comprise one or more hydrophilic organic UV-screening agents.

[0089] For the purposes of the present invention, the term “hydrophilic organic UV-screening agent” is understood to mean a water-soluble organic UV-screening agent or a water-dispersible organic UV-screening agent.

[0090] Among the water-soluble organic UVA-screening agents that may be used according to the present invention, mention may be made of benzene-1,4-bis(3-methylidene-10-camphorsulfonic) acid (INCI name: Terephthalylidene Dicamphor Sulfonic Acid) and the various salts thereof, notably described in patent applications FR-A-2528420 and FR-A-2639347. Mention may notably be made of benzene-1,4-bis(3-methylidene-10-camphorsulfonic) acid (INCI name: Terephthalylidene Dicamphor Sulfonic Acid) such as the product which is produced under the name Mexoryl® SX by Noveal.

[0091] These screening agents correspond to the general formula (I) below: in which F denotes a hydrogen atom, an alkali metal or else an NH(R1)3+radical in which the R1radicals, which may be identical or different, denote a hydrogen atom, a C1to C4alkyl or hydroxyalkyl radical or else an Mn+group, Mn+denoting a polyvalent metal cation in which n is equal to 2 or 3 or 4, Mn+preferably denoting a metal cation chosen from Ca2+, Zn2+, Mg2+, Ba2+, Al3+and Zr4+. It is clearly understood that the compounds of formula (I) above can give rise to the “cis-trans” isomer around one or more double bond(s) and that all the isomers come within the context of the present invention.

[0092] Among the water-soluble organic UVA-screening agents that can be used according to the present invention, mention may also be made of compounds including at least two benzazolyl groups bearing sulfonic groups, such as those described in patent application EP-A-0669323.

[0093] They are described and prepared according to the syntheses indicated in patent US 2 463 264 and also in patent application EP-A-0669323.

[0094] The compounds including at least two benzazolyl groups in accordance with the invention correspond to the general formula (II) below: (II)in which,- Z represents an organic residue of valency (l + n) comprising one or more double bonds placed such that it completes the system of double bonds of at least two benzazolyl groups as defined inside the square brackets so as to form a fully conjugated assembly;- X’ denotes S, O or NR6;- R1denotes a hydrogen atom, a C1to C18alkyl, a C1to C4alkoxy, a C5to C15aryl, a C2to C18acyloxy, or an SO3Y or COOY group;- - the R2, R3, R4and R5radicals, which may be identical or different, denote a nitro group or an R1radical;- R6denotes a hydrogen atom, a C1to C4alkyl or a C1to C4hydroxyalkyl;- Y denotes a hydrogen atom, Li, Na, K, NH4, 1 / 2Ca, 1 / 2Mg, 1 / 3Al or a cation resulting from the neutralization of a free acid group with an organic nitrogen base;- m is 0 or 1;- n is a number from 2 to 6;- l is a number from 1 to 4;- with the proviso that l + n does not exceed the value 6.

[0095] Among these compounds, very particular preference is given to 1,4-bis-benzimidazolyl-phenylene-3,3’,5,5’-tetrasulfonic acid (INCI name: Disodium Phenyl Dibenzimidazole Tetrasulfonate) or a salt thereof, having the following structure (III), sold in particular under the name Neo Heliopan® AP by Symrise: (III)

[0096] Preferably, the water-soluble screening agent that is capable of absorbing UVA rays is benzene-1,4-bis(3-methylidene-10-camphorsulfonic) acid (INCI name: Terephthalylidene Dicamphor Sulfonic Acid) such as the product which is produced under the name Mexoryl SX by Noveal.

[0097] The water-soluble organic UVB-screening agents that can be used according to the present invention are notably chosen from water-soluble cinnamic derivatives, such as ferulic acid or 3-methoxy-4-hydroxycinnamic acid; water-soluble benzylidene camphor compounds; water-soluble phenylbenzimidazole compounds; water-soluble p-aminobenzoic (PABA) compounds; water-soluble salicylic compounds, and mixtures thereof.

[0098] Mention may be made, as examples of water-soluble organic UVB-screening agents, of phenylbenzimidazole compounds, such as 2-phenyl-1H-benzimidazole-5-sulfonic acid (INCI name: phenylbenzimidazole sulfonic acid) sold in particular under the trade name Eusolex 232®by Merck.

[0099] The composition according to the invention may also comprise at least one hybrid water-soluble screening agent capable of absorbing UVA and UVB rays.

[0100] When the water-soluble UV-screening agent is of sulfonic acid type, it is preferably associated with an organic base, such as an alkanolamine.

[0101] The term “alkanolamine” means a C2-C10compound comprising at least one primary, secondary or tertiary amine function and at least one alcohol, generally primary alcohol, function. As suitable alkanolamines, mention may be made of 2-amino-2-(hydroxymethyl)-1,3-propanediol (INCI name: Tromethamine) and triethanolamine.

[0102] Among the water-dispersible organic screening agents, mention may be made of the following screening agents.

[0103] Benzophenone compounds:1,1’-(1,4-Piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]methanone] (CAS 919803-06-8), as described in patent application WO 2007 / 071584; this compound advantageously being used in micronized form (volume-average size of 0.02 to 2 µm), which may be obtained, for example, according to the micronization process described in patent applications GB-A-2 303 549 and EP-A-893 119, and in particular in the form of an aqueous dispersion,

[0104] Methylene bis(hydroxyphenylbenzotriazole) compounds:Methylene bis(benzotriazolyl)tetramethylbutylphenolin the form of an aqueous dispersion of micronized particles with a volume-average particle size which ranges from 0.01 to 5 µm, more preferentially from 0.01 to 2 µm and more particularly from 0.020 to 2 µm, with at least one alkyl polyglycoside surfactant having the structure CnH2n+1O(C6H10O5)xH, in which n is an integer from 8 to 16 and x is the mean degree of polymerization of the (C6H10O5) unit and ranges from 1.4 to 1.6 such as the aqueous dispersions described in patent GB-A-2 303 549, in particular the product sold under the trade name Tinosorb® M by BASF, orin the form of an aqueous dispersion of micronized particles with a volume-average particle size which ranges from 0.02 to 2 µm, and more preferentially from 0.01 to 1.5 µm and more particularly from 0.02 to 1 µm, in the presence of at least one polyglyceryl mono(C8-C20)alkyl ester with a degree of glycerol polymerization of at least 5, such as the aqueous dispersions described in patent application WO 2009 / 063392, in particular the product sold under the name Tinosorb WPGL by BASF,

[0105] Triazine compounds:- Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine in its water-dispersible form having the INCI name Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine (and) Acrylates / C12-22 Alkyl Methacrylate Copolymer, under the trade name Tinosorb® S LiteAqua by BASF,- symmetrical triazine screening agents substituted with naphthalenyl groups or polyphenyl groups used in micronized form (mean particle size of 0.02 to 3 µm) which may be obtained, for example, via the micronization process described in patent applications GB-A-2 303 549 and EP-A-893119, and notably in aqueous dispersion form, notably 2,4,6-tris(biphenyl)triazine and 2,4,6-tris(terphenyl)triazine sold under the name Tinosorb® A2B by BASF and included in patent applications WO 06 / 035000, WO 06 / 034982, WO 06 / 034991, WO 06 / 035007, WO 2006 / 034992 and WO 2006 / 034985,

[0106] Benzoxazole compounds:2-[4-(1,3-benzoxazol-2-yl)phenyl]-1,3-benzoxazole, having the CAS number 904-39-2.Inorganic UV-screening agents

[0107] The composition in accordance with the invention may comprise at least one inorganic UV-screening agent.

[0108] The inorganic UV-screening agents that may be used in accordance with the present invention are metal oxide pigments. More preferentially, the inorganic UV-screening agents of the invention are metal oxide particles having an average elementary particle size of less than or equal to 0.5 µm, more preferentially of between 0.005 and 0.5 µm, even more preferentially of between 0.01 and 0.2 µm, even better still between 0.01 and 0.1 µm and more particularly between 0.015 and 0.05 µm. They are notably described in Annex VI, updated on 22 / 09 / 2021, of the European regulation number 1223 / 2009 on cosmetic products, but are not limited to that list.

[0109] They may notably be chosen from titanium oxide, zinc oxide, iron oxide, zirconium oxide and cerium oxide, or mixtures thereof.

[0110] Such coated or uncoated metal oxide pigments are described in particular in patent application EP-A-0 518 773. Commercial pigments that may be mentioned include the products sold by the companies Croda, Tayca and Merck.

[0111] The metal oxide pigments may be coated or uncoated.

[0112] The coated pigments are pigments which have undergone one or more surface treatments of chemical, electronic, mechanochemical and / or mechanical nature with compounds such as amino acids, beeswax, fatty acids, fatty alcohols, anionic surfactants, lecithins, sodium, potassium, zinc, iron or aluminum salts of fatty acids, metal alkoxides (of titanium or aluminum), polyethylene, silicones, proteins (collagen, elastin), alkanolamines, silicon oxides, metal oxides or sodium hexametaphosphate.

[0113] The coated pigments are more particularly titanium oxides that have been coated:- with hydrated silica, such as the product MT-100WP from Tayca,- with silica and iron oxide, such as the product Sunveil F® from Ikeda,- with silica and alumina, such as the products MT-500SA® and MT-100SA® from Tayca and Tioveil™ AQ-N from Croda,- with alumina, such as the product TTO-55 (A)® from Ishihara,- with alumina and aluminum stearate, such as the products MT-100TV®, MT-100Z® and MT-01® from Tayca, the product Solaveil™ CT100 from Croda and the product Eusolex T-AVO® from Merck,- with silica, alumina and alginic acid, such as the product MT-100AQ® from Tayca,- with alumina and aluminum laurate,- with iron oxide and iron stearate,- with zinc oxide and zinc stearate,- with silica and alumina and treated with a silicone, such as the products MTY-500SAS® or Microtitanium Dioxide MT-100SAS® from Tayca,- with silica, alumina, and aluminum stearate and treated with a silicone,- with silica and treated with a silicone,- with alumina and treated with a silicone, such as the product TTO-55(S)® from Ishihara,- with triethanolamine,- with stearic acid, such as the product TTO-55 (C)® from Ishihara,- with sodium hexametaphosphate,- TiO2treated with octyltrimethylsilane,- TiO2treated with a polydimethylsiloxane,- anatase / rutile TiO2treated with a polydimethylhydrosiloxane,- TiO2coated with triethylhexanoin, with aluminum stearate and with alumina sold under the trade name Solaveil™ CT-200 by Croda,- TiO2coated with aluminum stearate, with alumina and with silicone, sold under the trade name Solaveil™ CT-12W by Croda,- TiO2coated with lauroyl lysine,- TiO2coated with C9-C15 fluoroalcohol phosphate and with aluminum hydroxide.

[0114] Mention may also be made of TiO2pigments doped with at least one transition metal such as iron, zinc or manganese and more particularly manganese. Preferably, said doped pigments are in the form of an oily dispersion. The oil present in the oily dispersion is preferably chosen from triglycerides including those of capric / caprylic acids. The oily dispersion of titanium oxide particles may also comprise one or more dispersants, for instance a sorbitan ester, for instance sorbitan isostearate, or a polyoxyalkylenated fatty acid ester of glycerol, for instance Tri-PPG-3 myristyl ether citrate and polyglyceryl-3 polyricinoleate. Preferably, the oily dispersion of titanium oxide particles includes at least one dispersant chosen from polyoxyalkylenated fatty acid esters of glycerol. Mention may be made more particularly of the oily dispersion of TiO2particles doped with manganese in capric / caprylic acid triglyceride in the presence of Tri-PPG-3 myristyl ether citrate and polyglyceryl-3 polyricinoleate and sorbitan isostearate having the INCI name: Titanium Dioxide (and) Tri-PPG-3 Myristyl Ether Citrate (and) Polyglyceryl-3 Ricinoleate (and) Sorbitan Isostearate, or the product sold under the trade name OptisolTM.OTP-1 by Croda.

[0115] The uncoated titanium oxide pigments are for example sold by Tayca under the trade names MT-500B or MT-600B® or by Evonik under the name Degussa P 25.

[0116] The uncoated zinc oxide pigments are, for example:- those sold under the name Z-Cote® by BASF;- those sold under the name NanoArc® Zinc Oxide by Nanophase Technologies.

[0117] The coated zinc oxide pigments are, for example:- ZnO coated with polymethylhydrosiloxane;- Solaveil™ CZ-100 from Croda, dispersed in C12-C15 alkyl benzoate (INCI: Zinc Oxide (and) C12-15 Alkyl Benzoate (and) Polyhydroxystearic Acid (and) Isostearic Acid);- those sold under the name Daitopersion Zn-60VA® by Daito Kasei (dispersions in C9-C12 alkane with a dispersant);- those sold under the name SPD-Z5® by Shin-Etsu (ZnO coated with silicone-grafted acrylic polymer, dispersed in cyclodimethylsiloxane).

[0118] The uncoated cerium oxide pigments may be, for example, those sold under the name Rhodigard® W185 by Solvay.

[0119] Mention may also be made of mixtures of metal oxides, notably of titanium dioxide and of cerium dioxide, including the equal-weight mixture of titanium dioxide and cerium dioxide coated with silica, and also the mixture of titanium dioxide and zinc dioxide coated with alumina, silica and silicone, or coated with alumina, silica and glycerol.

[0120] When the composition in accordance with the invention comprises inorganic UV-screening agents, coated or uncoated titanium oxide pigments are particularly preferred.

[0121] According to one particular embodiment of the invention, the composition is free of inorganic screening agents.

[0122] For the purposes of the present invention, the expression “free of inorganic UV-screening agents” is understood to mean an amount of inorganic UV-screening agents of less than 2% by weight, preferably less than 1% by weight, and even more preferentially less than 0.5% by weight relative to the total weight of the composition. Preferably, the composition in accordance with the invention does not comprise any inorganic UV-screening agents.

[0123] The UV-screening agents can be present in the composition according to the invention in a content ranging from 0.1% to 60% by weight, preferably from 1% to 40% by weight, and even more preferentially from 5% to 30% by weight, and better still from 10% to 25% by weight, relative to the total weight of the composition.Gemini surfactants

[0124] The composition in accordance with the invention comprises at least one gemini surfactant.

[0125] The gemini surfactant(s) are chosen from the compounds of formula (IV), and also the stereoisomers thereof: (IV)wherein:R1and R3denote, independently of one another, an alkyl radical having from 1 to 25 carbon atoms;R2denotes a spacer constituted of a linear or branched alkylene chain having from 1 to 12 carbon atoms;X and Y denote, independently of one another, a –(C2H4O)a-(C3H6O)bZ group where:- Z denotes a hydrogen atom or a –CH2-COOM, -SO3M, -P(O)(OM)2, –C2H4-SO3M, –C3H6-SO3M or –CH2(CHOH)4CH2OH radical, where M represents H or an alkali metal ion or alkaline-earth metal ion or ammonium ion or alkanolammonium ion,- a ranges from 0 to 15,- b ranges from 0 to 10, and- the sum of a + b ranges from 1 to 25; and- n ranges from 1 to 10.

[0126] According to one preferred embodiment, the gemini surfactant(s) of formula (IV) are such that each of the R1-CO- and R3-CO- groups comprises from 8 to 20 carbon atoms, and preferably denotes a coconut fatty acid residue (mainly comprising lauric acid and myristic acid).

[0127] According to another preferred embodiment, the gemini surfactant(s) of formula (IV) are such that, for each of the X and Y radicals, the sum of a and b has an average value ranging from 10 to 20 and is preferably equal to 15. A preferred group for Z is the -SO3M group, where M is preferably an alkali metal ion, such as a sodium ion.

[0128] In formula (B) as defined above, the spacer R2is advantageously constituted of a linear C1-C3alkylene chain, and preferably a (CH2CH2) ethylene chain.

[0129] Finally, n is advantageously equal to 1.

[0130] A surfactant of this type is in particular the one identified by the INCI name Sodium dicocoylethylenediamine PEG-15 sulfate having the following structure: it being understood that PEG represents the CH2CH2O group and cocoyl represents the coconut fatty acid residue.

[0131] This surfactant has a molecular structure very similar to that of ceramide-3.

[0132] According to a particular embodiment, the gemini surfactant of formula (IV) of the invention is used as a mixture with other surfactants.

[0133] According to a preferred embodiment, the gemini surfactant of formula (IV) of the invention is used as a mixture with a glycerol diester of a C6-C22fatty acid (preferably C14-C20, such as a stearate) and of citric acid.

[0134] Preferably, the gemini surfactant of formula (IV) of the invention is used as a mixture with (a) a glycerol ester of a C6-C22fatty acid (preferably C14-C20such as a stearate), (b) a glycerol diester of a C6-C22fatty acid (preferably C14-C20such as a stearate) and of citric acid, and (c) a C10-C30fatty alcohol (preferably behenyl alcohol).

[0135] More preferentially, the gemini surfactant of formula (IV) according to the invention represents from 10% to 20% by weight and advantageously 15% by weight; the glycerol ester of a C6-C22fatty acid represents from 30% to 40% by weight, advantageously 35% by weight; the glycerol diester of a C6-C22fatty acid and of citric acid represents from 10% to 20% by weight, advantageously 15% by weight; and the C10-C30fatty alcohol represents from 30% to 40% by weight, advantageously 35% by weight, relative to the total weight of the mixture of surfactants containing the gemini surfactant.

[0136] As a variant, the gemini surfactant of formula (IV) according to the invention may be used as a mixture with an anionic surfactant, such as a lauric acid ester, sodium lauryl lactate. In this case, the gemini surfactant preferably represents from 30% to 50% by weight, and the anionic surfactant represents from 30% to 50% by weight, relative to the total weight of the mixture.

[0137] The gemini surfactant may be used, for example, as a mixture with other surfactants in the form of the products sold by Sasol under the name Ceralution®, and notably the following products:• Ceralution®H: Behenyl Alcohol, Glyceryl Stearate, Glyceryl Stearate Citrate and Sodium Dicocoylethylenediamine PEG-15 Sulfate,• Ceralution®F: Sodium Lauroyl Lactylate and Sodium Dicocoylethylenediamine PEG-15 Sulfate,• Ceralution®C: Aqua, Capric / Caprylic triglyceride, Glycerin, Ceteareth-25, Sodium Dicocoylethylenediamine PEG-15 Sulfate, Sodium Lauroyl Lactylate, Behenyl Alcohol, Glyceryl Stearate, Glyceryl Stearate Citrate, Gum Arabic, Xanthan Gum, Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Isobutylparaben (INCI names).

[0138] According to one particular embodiment of the invention, the gemini surfactant(s) of formula (IV) are in the form of a mixture of surfactants comprising from 3% to 50% by weight of gemini surfactants of formula (IV), preferably from 10% to 50% by weight, and even more preferentially from 10% to 20% by weight, relative to the total weight of the mixture.

[0139] The gemini surfactant(s) of formula (IV) can be present in the composition according to the invention in a content of active material ranging from 0.01% to 5% by weight, relative to the total weight of the composition, preferably ranging from 0.1% to 3% by weight and better still ranging from 0.2% to 1.5% by weight.C1-C4 monoalkanol

[0140] The composition in accordance with the invention comprises at least one C1-C4monoalkanol.

[0141] For the purposes of the present invention, a “C1-C4monoalkanol” is understood to mean any linear or branched saturated alkane compound containing from 1 to 4 carbon atoms and only one hydroxy (OH) function.

[0142] The C1-C4monoalkanol(s) present in the compositions of the invention may be chosen from methanol, ethanol, propanol and isopropanol, or mixtures thereof. Ethanol will be chosen more particularly.

[0143] According to a preferred embodiment, the composition in accordance with the invention comprises at least 8% by weight, preferably at least 10% by weight, relative to the total weight of the composition, of C1-C4monoalkanols, notably ethanol.

[0144] Preferably, their concentration is generally between 8% and 90% by weight, in particular from 8% to 70% by weight, and even more preferentially from 9% to 60% by weight, better still from 10% to 25% by weight, relative to the total weight of the composition.

[0145] Carboxylic or carboxylate anionic surfactants chosen from fatty-chain amino acids and salts thereof

[0146] According to one particular embodiment, the composition in accordance with the invention comprises at least one carboxylic or carboxylate anionic surfactant chosen from amino acids modified with at least one C8-C30, preferably C10-C24, and even more preferentially C16-C22, hydrocarbon chain, and salts thereof.

[0147] The term “hydrocarbon chain” is intended to mean a linear or branched, saturated or unsaturated organic group constituted mainly of hydrogen atoms and carbon atoms, in which one or more carbon atoms can be replaced with an oxygen atom or a nitrogen atom. As examples of C8-C30hydrocarbon chains, mention may be made of C8-C30acyl radicals.

[0148] By way of examples of amino acids, mention may be made of alanine, arginine, aspartic acid, glutamic acid, glycine, isoleucine, leucine, lysine, phenylalanine, serine, tyrosine, valine and sarcosine.

[0149] More specifically, mention may be made, by way of carboxylate anionic surfactants chosen from the salts of amino acids modified with at least one fatty chain, of the following compounds: dipotassium capryloyl glutamate, dipotassium undecylenoyl glutamate, disodium capryloyl glutamate, disodium cocoyl glutamate, disodium lauroyl glutamate, disodium stearoyl glutamate, disodium undecylenoyl glutamate, potassium capryloyl glutamate, potassium cocoyl glutamate, potassium lauroyl glutamate, potassium myristoyl glutamate, potassium stearoyl glutamate, potassium undecylenoyl glutamate, sodium capryloyl glutamate, sodium cocoyl glutamate, sodium lauroyl glutamate, sodium myristoyl glutamate, sodium olivoyl glutamate, sodium palmitoyl glutamate, sodium stearoyl glutamate, sodium undecylenoyl glutamate, cocoyl methyl β-alaninate, lauroyl β-alaninate, lauroyl methyl β-alaninate, myristoyl β-alaninate, potassium lauroyl methyl β-alaninate, sodium cocoyl alaninate, sodium cocoyl methyl β-alaninate and sodium myristoyl methyl β-alaninate, sodium palmitoyl glycinate, sodium lauroyl glycinate, sodium cocoyl glycinate, sodium myristoyl glycinate, potassium lauroyl glycinate, potassium cocoyl glycinate, potassium lauroyl sarcosinate, potassium cocoyl sarcosinate, sodium cocoyl sarcosinate, sodium lauroyl sarcosinate, sodium myristoyl sarcosinate, sodium oleoyl sarcosinate, sodium palmitoyl sarcosinate, ammonium lauroyl sarcosinate, sodium lauroyl aspartate, sodium myristoyl aspartate, sodium cocoyl aspartate, sodium caproyl aspartate, disodium lauroyl aspartate, disodium myristoyl aspartate, disodium cocoyl aspartate, disodium caproyl aspartate, potassium lauroyl aspartate, potassium myristoyl aspartate, potassium cocoyl aspartate, potassium caproyl aspartate, dipotassium lauroyl aspartate, dipotassium myristoyl aspartate, dipotassium cocoyl aspartate, dipotassium caproyl aspartate, and mixtures thereof.

[0150] According to one particular embodiment of the invention, the carboxylic or carboxylate anionic surfactant(s) are chosen from the compounds having the following structure (V): (V)in which:Z represents a linear or branched, saturated or unsaturated hydrocarbon group comprising from 8 to 30 carbon atoms, preferably from 10 to 24, and even more preferentially from 16 to 22, carbon atoms;X is a hydrogen atom or a methyl group;n is equal to 0 or 1;Y is a group chosen from a hydrogen atom, a -CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -CH2C6H5, -CH2C2H4OH, -CH2OH, -CH(OH)CH3, -(CH2)4NH2, -(CH2)3NHC(NH)NH2, -CH2C(O)O-M+, -(CH2)2C(O)OH or -(CH2)2C(O)O-M+group; andM is a hydrogen atom or a cation such as sodium, potassium, ammonium or triethanolamine.

[0151] According to one preferred embodiment, in formula (V):Z represents a linear or branched C8-C24alkyl or alkenyl group;X is a hydrogen atom or a methyl radical;n is equal to 0;Y is a hydrogen atom, a -(CH2)2C(O)OH group or a -(CH2)2C(O)O-M+group; andM is a cation such as sodium, potassium, ammonium or triethanolamine.

[0152] According to one particular embodiment, the composition according to the invention comprises at least one acyl glutamic acid (INCI name: acyl glutamic acid) or a salt thereof (acyl glutamates).

[0153] Preferably, the acyl glutamic acid(s) are chosen from acyl glutamic acids in which the acyl group comprises from 8 to 30 carbon atoms, preferably from 10 to 24 carbon atoms and even more preferentially from 16 to 22 carbon atoms, such as lauroyl glutamic acid, myristoyl glutamic acid, palmitoyl glutamic acid, stearoyl glutamic acid, behenoyl glutamic acid, olivoyl glutamic acid, cocoyl glutamic acid, and the salts of these acids, especially the salts of alkali metals such as Na, Li or K, preferably Na or K, the salts of alkaline-earth metals such as Mg, or the ammonium salts of said acids.

[0154] Preferably, mention may be made, by way of salts of amino acids modified with at least one C8-C30hydrocarbon chain, of glutamate salts, and in particular dipotassium capryloyl glutamate, dipotassium undecylenoyl glutamate, disodium capryloyl glutamate, disodium cocoyl glutamate, disodium lauroyl glutamate, disodium stearoyl glutamate, disodium undecylenoyl glutamate, potassium capryloyl glutamate, potassium cocoyl glutamate, potassium lauroyl glutamate, potassium myristoyl glutamate, potassium stearoyl glutamate, potassium undecylenoyl glutamate, sodium capryloyl glutamate, sodium cocoyl glutamate, sodium lauroyl glutamate, sodium myristoyl glutamate, sodium olivoyl glutamate, sodium palmitoyl glutamate, sodium stearoyl glutamate, sodium undecylenoyl glutamate.

[0155] Preferably, the acyl glutamic acid(s) or a salt thereof are chosen from lauroyl glutamic acids, cocoyl glutamic acids, sodium stearoyl glutamate, potassium lauroyl glutamate, potassium cocoyl glutamate, sodium olivoyl glutamate and mixtures thereof.

[0156] More preferentially, the acyl glutamic acid or a salt thereof is sodium stearoyl glutamate (INCI name).

[0157] Such compounds are sold under the name Amisoft by Ajinomoto and in particular under the references Amisoft CA, Amisoft LA, Amisoft HS 11 PF, Amisoft MK-11, Amisoft LK-11 and Amisoft CK-11, or alternatively under the name Eumulgin SG by Cognis.

[0158] Mention may also be made of triethanolamine cocoyl glutamate sold under the name Amisoft CT12 by Ajinomoto, and triethanolamine lauroyl glutamate sold under the name Acylglutamate LT-12 by Ajinomoto.

[0159] As acyl glutamic acid salts, mention may also be made of sodium hydrogenated tallowoyl glutamate, such as the product sold under the reference Acylglutamate HS 11 by Ajinomoto and disodium hydrogenated tallow glutamate, such as the product sold under the reference Acylglutamate HS-21 by Ajinomoto.

[0160] Mention may also be made of commercial mixtures of surfactants comprising at least one glutamic acid derivative or a salt of said derivative, for instance the mixture of acyl glutamate salts such as Amisoft LS-22 sold by Ajinomoto.

[0161] According to one preferred embodiment of the invention, the monosodium salt of n-stearoyl-L-glutamic acid (INCI name: sodium stearoyl glutamate), such as the product sold by Ajinomoto under the reference Amisoft HS 11 PF, is used.

[0162] The amino acid(s) modified with at least one C8-C30hydrocarbon chain, and salts thereof, may be present in the composition in a content ranging from 0.01% to 5% by weight, preferably from 0.01% to 2% by weight, more preferentially from 0.05% to 1% by weight, better still from 0.1% to 0.8% by weight, and even better still from 0.1% to 0.5% by weight, relative to the total weight of the composition.

[0163] Semicrystalline polymer containing at least one alkyl acrylate chain

[0164] According to one particular embodiment, the composition according to the invention comprises at least one semicrystalline polymer containing at least one alkyl acrylate chain, the alkyl radicals preferably being C16-C22radicals.

[0165] For the purposes of the invention, a “semicrystalline polymer” is understood to mean polymers comprising a crystallizable portion, pendent chain or block in the backbone, and an amorphous portion in the backbone, and having a reversible first-order phase transition temperature, in particular melting point (solid-liquid transition).

[0166] When the crystallizable portion is a block of the polymer backbone, this crystallizable block is of different chemical nature from that of the amorphous blocks; the semicrystalline polymer is, in this case, a block polymer, for example of the diblock, triblock or multiblock type, comprising at least one crystallizable block and at least one amorphous block.

[0167] The term “block” is generally understood to mean at least 5 identical repeating units. The crystallizable block(s) are then of different chemical nature from the 5 amorphous block(s).

[0168] Advantageously, the semicrystalline polymer containing at least one alkyl acrylate chain of the composition of the invention has an average molecular mass (Mn) of greater than or equal to about 2000 g / mol, preferably from about 2000 to 800 000 g / mol, preferably from about 3000 to 500 000 g / mol, preferably from about 4000 to 150 000 g / mol, and preferably from about 5000 to 130 000 g / mol.

[0169] Aside from the crystallizable chains or blocks, the blocks of the polymers are amorphous.

[0170] For the purposes of the invention, the term “crystallizable chain or block” is understood to mean a chain or block which, if it were alone, would change from the amorphous state to the crystalline state reversibly, depending on whether the temperature is above or below the melting point. For the purposes of the invention, a chain is a group of atoms, which is pendent or lateral relative to the polymer backbone. A block is a group of atoms belonging to the backbone, this group constituting one of the repeating units of the polymer. Advantageously, the “pendent crystallizable chain” may be a chain containing at least 6 carbon atoms.

[0171] Preferably, the polymer backbone of the semicrystalline polymers is soluble in the oily phase.

[0172] Thus, the semicrystalline polymer containing at least one alkyl acrylate chain that is used in the composition of the invention is generally introduced into the oily phase of the composition.

[0173] Preferably, the crystallizable blocks or chains of the semicrystalline polymers containing at least one alkyl acrylate chain represent at least approximately 30% by weight and preferably at least approximately 40% by weight relative to the total weight of each polymer.

[0174] The semicrystalline polymers comprising crystallizable blocks used according to the invention are block or multiblock polymers. They may be obtained by polymerizing monomers bearing reactive (or ethylenic) double bonds or by polycondensation. When the polymers of the invention are polymers bearing crystallizable side chains, these polymers are advantageously in random or statistical form.

[0175] The semicrystalline polymers of the invention may be of synthetic origin. Moreover, they do not comprise a polysaccharide backbone.

[0176] The semicrystalline polymers of the composition of the invention may or may not be partially crosslinked. It may then be a case of chemical crosslinking, by reaction with a multifunctional monomer during the polymerization. It may also be a case of physical crosslinking, which may then be due either to the establishment of bonds of hydrogen or dipolar type between groups borne by the polymer, such as dipolar interactions between carboxylate ionomers, these interactions being in small amount and borne by the polymer backbone; or due to a phase separation between the crystallizable blocks and the amorphous blocks borne by the polymer.

[0177] Preferably, the semicrystalline polymers containing at least one alkyl acrylate chain of the composition according to the invention are non-crosslinked.

[0178] As examples of semicrystalline polymers according to the invention containing at least one alkyl acrylate chain, mention may be made of those resulting from the polymerization of one or more saturated alkyl (meth)acrylates.

[0179] Preferably, the semicrystalline polymers bearing a crystallizable side chain are alkyl (meth)acrylate homopolymers, or copolymers of these monomers with a hydrophilic monomer.

[0180] According to a particular embodiment of the invention, the semicrystalline polymer containing at least one alkyl acrylate chain is derived from a monomer bearing a crystallizable chain chosen from saturated alkyl (meth)acrylates and even more particularly poly(stearyl acrylate)s or poly(behenyl acrylate)s.

[0181] According to another particular embodiment of the invention, the semicrystalline polymer containing at least one alkyl acrylate chain is chosen from copolymers resulting from the polymerization of at least one monomer bearing a crystallizable chain and chosen from saturated alkyl (meth)acrylates.

[0182] According to a preferred embodiment, the semicrystalline polymer containing at least one alkyl acrylate chain is chosen from the homopolymers obtained by polymerization of a monomer chosen from alkyl acrylates and alkyl methacrylates and from the copolymers obtained by copolymerization of a monomer chosen from alkyl acrylates and alkyl methacrylates with a hydrophilic monomer, preferably N-vinylpyrrolidone or a hydroxyethyl (meth)acrylate, and mixtures thereof, more preferentially still a hydroxyethyl (meth)acrylate, and mixtures thereof.

[0183] As particular examples of semicrystalline polymers that can be used in the composition according to the invention, mention may be made of the homopolymers obtained by polymerization of a monomer chosen from alkyl acrylates and alkyl methacrylates, preferably from stearyl acrylates and behenyl acrylates, notably the polymers having the INCI name Poly C10-30 Alkyl Acrylate such as the Tego® SP products from Evonik, notably the product TEGO CARE SP 13-1, which is a polystearyl acrylate, or the product TEGO CARE SP 13-6, which is a behenyl polymer (polybehenyl acrylate).

[0184] As particular examples of semicrystalline polymers that can be used in the composition, mention may also be made of the copolymers obtained by copolymerization of a monomer chosen from alkyl acrylates and alkyl methacrylates with a hydrophilic monomer, preferably a hydroxyethyl (meth)acrylate, notably the copolymers described in patent applications FR 3 073 405 and FR 3 073 406, and preferably the copolymers obtained by copolymerization of at least one monomer chosen from alkyl acrylates, preferably from behenyl acrylates, stearyl acrylates, and mixtures thereof, with a hydrophilic monomer such as hydroxyethyl (meth)acrylate and N-vinylpyrrolidone, and preferably hydroxyethyl acrylate.

[0185] Preferably, the semicrystalline polymer containing at least one alkyl acrylate chain is a behenyl acrylate / 2-hydroxyethyl acrylate copolymer, a stearyl acrylate / 2-hydroxyethyl acrylate copolymer and / or a mixture thereof, and in particular the polymer with the INCI name: Poly C12-22 Alkyl Acrylate / Hydroxyethyl Acrylate Copolymer sold in particular under the name Tego SP Senstar by Evonik.

[0186] According to a preferred embodiment, the semicrystalline polymer(s) containing at least one alkyl acrylate chain are chosen from a polystearyl acrylate, a polybehenyl acrylate, a behenyl acrylate / 2-hydroxyethyl acrylate copolymer, a stearyl acrylate / 2-hydroxyethyl acrylate copolymer, and a mixture thereof, in particular chosen from the polymer with the INCI name: Poly C10-30 Alkyl Acrylate, the copolymer with the INCI name C12-22 Alkyl Acrylate / Hydroxyethyl Acrylate Copolymer, and mixtures thereof, more particularly the polymer with the INCI name: Poly C10-30 Alkyl Acrylate.

[0187] According to a more preferred embodiment, the semicrystalline polymer containing at least one alkyl acrylate chain is a polymer having the INCI name: Poly C10-30 Alkyl Acrylate.

[0188] The semicrystalline polymer(s) containing at least one alkyl acrylate chain may be present in the composition according to the invention in an active material content ranging from 0.05% to 10% by weight, relative to the total weight of the composition, preferably ranging from 0.1% to 5% by weight and better still ranging from 0.2% to 2% by weight, and even more preferentially from 0.5% to 1.5% by weight.Polyols

[0189] According to a particular embodiment, the composition in accordance with the present invention comprises one or more polyols comprising at least three hydroxy functions.

[0190] The term “"polyol comprising at least three hydroxy functions” according to the invention is understood to mean a hydrocarbon chain comprising at least 2 carbon atoms, preferably from 2 to 50 carbon atoms, better still from 2 to 20 carbon atoms, and preferentially having from 2 to 10 carbon atoms and even more preferentially from 2 to 6 carbon atoms, and bearing at least three hydroxy groups. Preferably, the polyols used in the present invention have an average molecular mass of less than or equal to 1000 g / mol and preferably within the range of from 85 to 500 g / mol.

[0191] Advantageously, the polyol comprising at least three hydroxy functions is a natural or synthetic polyol and has a linear, branched or cyclic molecular structure.

[0192] The polyol comprising at least three hydroxy functions is advantageously chosen from glycerol and derivatives thereof, and glycols comprising at least three hydroxy functions and derivatives thereof.

[0193] The polyol comprising at least three hydroxy functions is preferably chosen from glycerol, diglycerol, sugars, such as sorbitol, and mixtures thereof.

[0194] Preferably, the polyol comprising at least three hydroxy functions is glycerol.

[0195] The polyol(s) comprising at least three hydroxy functions may be present in the composition of the invention in a content within the range of from 0.05% to 20% by weight, better still from 0.1% to 15% by weight, and preferentially from 1% to 10% by weight, and even more preferentially from 2% to 6% by weight, relative to the total weight of the composition.Presentation form

[0196] According to a particular embodiment, the compositions in accordance with the invention are fluid and their viscosity at room temperature and atmospheric pressure is less than or equal to 150 mPa.s, preferably less than or equal to 100 mPa.s, even more preferentially less than or equal to 35 mPa.s, and better still less than or equal to 30 mPa.s.

[0197] According to a preferred embodiment, the viscosity at room temperature and atmospheric pressure of the compositions in accordance with the invention is between 10 mPa.s and 35 mPa.s.

[0198] According to a particular embodiment of the invention, the composition is in the form of an emulsion.

[0199] The term “emulsion” means any kinetically stable macroscopically homogeneous composition comprising at least two mutually immiscible phases; one being the continuous dispersing phase and the other being dispersed in said continuous phase in the form of droplets. The two phases are generally kinetically stabilized by at least one emulsifying system which may comprise at least one emulsifying surfactant.

[0200] A distinction is made between “direct” emulsions of the oil-in-water type, constituted of a continuous aqueous dispersing phase and a discontinuous oily dispersed phase, and “inverse” emulsions of the water-in-oil type, constituted of a continuous oily dispersing phase and a discontinuous aqueous dispersed phase. There are also multiple emulsions such as water-in-oil-in-water or oil-in-water-in-oil emulsions.

[0201] According to a preferred embodiment, the compositions in accordance with the invention are direct emulsions.

[0202] The composition according to the invention may comprise at least one emulsifier chosen from amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture. The emulsifiers are chosen appropriately according to the emulsion to be obtained (W / O or O / W).

[0203] Examples of W / O nonionic emulsifying surfactants that may be mentioned include alkyl esters or ethers of sorbitan, of glycerol, of polyol or of sugars; silicone surfactants, for instance dimethicone copolyols, such as the mixture of cyclomethicone and of dimethicone copolyol, sold under the name DC 5225 C® by Dow Corning, and alkyldimethicone copolyols such as laurylmethicone copolyol sold under the name Dow Corning 5200 Formulation Aid by Dow Corning; cetyldimethicone copolyol, such as the product sold under the name Abil EM 90R® by Goldschmidt, and the mixture of cetyldimethicone copolyol, of polyglyceryl isostearate (4 mol) and of hexyl laurate, sold under the name Abil WE O9® by Goldschmidt. One or more coemulsifiers, which may be chosen advantageously from the group comprising polyol alkyl esters, may also be added thereto.

[0204] Mention may also be made of non-silicone emulsifying surfactants, notably alkyl esters or ethers of sorbitan, of glycerol, of polyol or of sugars.

[0205] Polyol alkyl esters that may notably be mentioned include polyethylene glycol esters, for instance PEG-30 dipolyhydroxystearate, such as the product sold under the name Arlacel P135® by ICI.

[0206] Examples of glycerol and / or sorbitan esters that may be mentioned include polyglyceryl isostearate, such as the product sold under the name Isolan GI 34® by Goldschmidt; sorbitan isostearate, such as the product sold under the name Arlacel 987® by ICI; sorbitan isostearate and glycerol, such as the product sold under the name Arlacel 986® by ICI, and mixtures thereof.

[0207] Mention may be made, for the O / W emulsions, for example, as nonionic emulsifying surfactants, of polyoxyalkylenated (more particularly polyoxyethylenated and / or polyoxypropylenated) esters of fatty acids and of glycerol such as the ester of polyethylene glycol and of stearic acid having the INCI name PEG-100 Stearate, sold under the name Myrj S100-PA-(SG) by Croda; oxyalkylenated esters of fatty acids and of sorbitan; polyoxyalkylenated (in particular polyoxyethylenated and / or polyoxypropylenated) esters of fatty acids, optionally in combination with a glycerol fatty acid ester, such as the PEG-100 Stearate / Glyceryl Stearate mixture sold, for example, by ICI under the name Arlacel 165; oxyalkylenated (oxyethylenated and / or oxypropylenated) ethers of fatty alcohols; esters of sugars, such as sucrose stearate; or ethers of fatty alcohol and of sugar, in particular alkyl polyglucosides (APGs), such as decyl glucoside and lauryl glucoside, sold, for example, by Henkel under the respective names Plantaren 2000® and Plantaren 1200®, cetostearyl glucoside, optionally as a mixture with cetostearyl alcohol, sold, for example, under the name Montanov 68® by SEPPIC, under the name Tegocare CG90® by Goldschmidt and under the name Emulgade KE3302® by Henkel, and arachidyl glucoside, for example in the form of the mixture of arachidyl and behenyl alcohols and of arachidyl glucoside sold under the name Montanov 202® by SEPPIC. According to one particular embodiment of the invention, the mixture of the alkyl polyglucoside as defined above with the corresponding fatty alcohol can be in the form of a self-emulsifying composition, for example as described in document WO-A-92 / 06778.

[0208] As anionic surfactants making it possible to produce O / W emulsions, mention may also be made of hydrophobically modified polysaccharides, in particular inulins modified with hydrophobic chains such as alkyl carbamate groups, in particular C8-C18alkyl carbamate groups, and more particularly lauryl carbamate groups.

[0209] Examples of these compounds that may notably be mentioned include the product sold under the name Inutec SL1 by Creachem.Fatty phase

[0210] The composition in accordance with the invention may comprise at least one fatty phase.

[0211] The fatty phase may be constituted of all the fatty substances conventionally used in the cosmetic or dermatological fields; it may in particular comprise at least one oil. The fatty phase also comprises the lipophilic screening agent(s) present in the composition according to the invention.

[0212] The term “oil” is understood to mean any fatty substance that is in liquid form at room temperature (20-25°C) and atmospheric pressure (760 mmHg). These oils may be volatile or non-volatile.

[0213] For the purposes of the invention, the term “volatile oil” is understood to mean an oil that is capable of evaporating on contact with the skin or the keratin fiber in less than one hour, at room temperature and atmospheric pressure. The volatile oil(s) of the invention are volatile cosmetic oils, which are liquid at room temperature, having a non-zero vapor pressure, at room temperature and atmospheric pressure, ranging in particular from 0.13 Pa to 40 000 Pa (10-3to 300 mmHg), in particular ranging from 1.3 Pa to 13 000 Pa (0.01 to 100 mmHg) and more particularly ranging from 1.3 Pa to 1300 Pa (0.01 to 10 mmHg).

[0214] The term “non-volatile oil” is understood to mean an oil that remains on the skin or the keratin fiber at room temperature and atmospheric pressure for at least several hours, and that notably has a vapor pressure of less than 10-3mmHg (0.13 Pa).

[0215] For the purposes of the present invention, the term “hydrocarbon oil” means any oil predominantly comprising carbon and hydrogen atoms, and optionally one or more heteroatoms, in particular nitrogen and oxygen. Thus, these oils may notably contain one or more ester, ether, fluoro, carboxylic acid and / or alcohol groups.

[0216] The term “silicone oil” is intended to mean an oil comprising at least one silicon atom and notably at least one Si-O group.

[0217] As non-volatile hydrocarbon oils that can be used according to the invention, mention may notably be made of:(i) hydrocarbon oils of plant origin such as glyceride triesters which are generally triesters of fatty acids and glycerol, the fatty acids of which may have chain lengths ranging from C4to C24, it being possible for the latter to be linear or branched, saturated or unsaturated; these oils are in particular wheat germ oil, sunflower oil, grapeseed oil, sesame oil, corn oil, apricot kernel oil, castor oil, shea oil, avocado oil, olive oil, soybean oil, sweet almond oil, palm oil, rapeseed oil, cottonseed oil, hazelnut oil, macadamia oil, jojoba oil, alfalfa oil, poppy oil, pumpkin oil, marrow oil, blackcurrant oil, evening primrose oil, millet oil, barley oil, quinoa oil, rye oil, safflower oil, candlenut oil, passionflower oil, musk rose oil; or else caprylic / capric acid triglycerides such as those sold by Stéarinerie Dubois or those sold under the names Miglyol 810®, 812® and 818® by Dynamit Nobel;(ii) synthetic ethers having from 10 to 40 carbon atoms;(iii) linear or branched hydrocarbons of mineral or synthetic origin such as liquid petroleum jelly, polydecenes, hydrogenated polyisobutene such as Parleam, squalane, and mixtures thereof;(iv) synthetic esters such as oils of formula RCOOR’ in which R represents the residue of a linear or branched fatty acid containing from 1 to 40 carbon atoms and R’ represents a hydrocarbon chain that is notably branched, containing from 1 to 40 carbon atoms, with the proviso that R + R’ is ≥ 10, for instance purcellin oil (cetostearyl octanoate), isopropyl myristate, isopropyl palmitate, C12-C15alkyl benzoates, such as the product sold under the trade name Finsolv TN® or Witconol TN® by Witco or TEGOSOFT TN® by Evonik Goldschmidt, 2-ethylphenyl benzoate, such as the commercial product sold under the name X-TEND 226® by ISP, isopropyl lanolate, hexyl laurate, diisopropyl adipate, isononyl isononanoate, oleyl erucate, 2-ethylhexyl palmitate, isostearyl isostearate, diisopropyl sebacate such as the product sold under the name Dub Dis by Stéarinerie Dubois, alcohol or polyalcohol octanoates, decanoates or ricinoleates, such as propylene glycol dioctanoate; hydroxylated esters, such as isostearyl lactate, diisostearyl malate; and pentaerythritol esters; citrates or tartrates such as linear di(C12-C13)alkyl tartrates such as those sold under the name COSMACOL ETI® by Enichem Augusta Industriale and also linear di(C14-C15) alkyl tartrates such as those sold under the name COSMACOL ETL® by the same company; acetates;(v) fatty alcohols that are liquid at room temperature, bearing a branched and / or unsaturated carbon chain containing from 12 to 26 carbon atoms, for instance octyldodecanol, isostearyl alcohol, oleyl alcohol, 2-hexyldecanol, 2-butyloctanol or 2-undecylpentadecanol;(vi) carbonates, such as dicaprylyl carbonate, such as the product sold under the name Cetiol CC® by Cognis;and mixtures thereof.

[0218] Among the non-volatile hydrocarbon oils which can be used according to the invention, preference will be given more particularly to glyceride triesters and in particular to caprylic / capric acid triglycerides, synthetic esters and in particular diisopropyl adipate, diisopropyl sebacate, isopropyl palmitate, dicaprylyl carbonate, isononyl isononanoate, oleyl erucate, C12-C15alkyl benzoate, 2-ethylphenyl benzoate and fatty alcohols, in particular octyldodecanol. Preferably, the non-volatile hydrocarbon oils are chosen from diisopropyl adipate, diisopropyl sebacate, isopropyl palmitate and dicaprylyl carbonate.

[0219] As volatile hydrocarbon oils that can be used according to the invention, mention may notably be made of hydrocarbon oils containing from 8 to 16 carbon atoms and notably branched C8-C16alkanes, such as C8-C16isoalkanes of petroleum origin (also known as isoparaffins), such as isododecane (also known as 2,2,4,4,6-pentamethylheptane), isodecane or isohexadecane, the oils sold under the Isopar or Permethyl trade names, branched C8-C16esters, isohexyl neopentanoate, and mixtures thereof.

[0220] Mention may also be made of the alkanes described in the Cognis patent applications WO 2007 / 068 371 or WO 2008 / 155 059 (mixtures of distinct alkanes differing by at least one carbon). These alkanes are obtained from fatty alcohols, which are themselves obtained from coconut kernel or palm oil. Mention may be made of the mixtures of n-undecane (C11) and n-tridecane (C13) obtained in Examples 1 and 2 of patent application WO 2008 / 155 059 from Cognis. Mention may also be made of n-dodecane (C12) and n-tetradecane (C14) sold by Sasol respectively under the references Parafol 12-97 and Parafol 14-97®, and also mixtures thereof.

[0221] Other volatile hydrocarbon oils, for instance petroleum distillates, notably those sold under the name Shell Solt® by Shell, may also be used. According to one embodiment, the volatile solvent is chosen from volatile hydrocarbon oils containing from 8 to 16 carbon atoms, and mixtures thereof.

[0222] The non-volatile silicone oils may be notably chosen from non-volatile polydimethylsiloxanes (PDMSs), polydimethylsiloxanes including alkyl or alkoxy groups which are pendent and / or at the end of the silicone chain, these groups each containing from 2 to 24 carbon atoms, or phenyl silicones, such as phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes or 2-phenylethyl trimethylsiloxysilicates.

[0223] Volatile silicone oils that may be mentioned, for example, include volatile linear or cyclic silicone oils, notably those with a viscosity ≤ 8 centistokes (8×10-6m2 / s) and notably containing from 2 to 7 silicon atoms, these silicones optionally including alkyl or alkoxy groups containing from 1 to 10 carbon atoms. As volatile silicone oils that may be used in the invention, mention may notably be made of octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, heptamethylhexyltrisiloxane, heptamethyloctyltrisiloxane, hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane and dodecamethylpentasiloxane, and mixtures thereof.

[0224] Mention may also be made of linear volatile alkyltrisiloxanes such as:3-butyl-1,1,1,3,5,5,5-heptamethyltrisiloxane,3-propyl-1,1,1,3,5,5,5-heptamethyltrisiloxane, and3-ethyl-1,1,1,3,5,5,5-heptamethyltrisiloxane.

[0225] Use may also be made of volatile fluoro oils, such as nonafluoromethoxybutane, nonafluoromethoxybutane, decafluoropentane, tetradecafluorohexane, dodecafluoropentane, and mixtures thereof.

[0226] The fatty phase according to the invention can additionally comprise other fatty substances, mixed with or dissolved in the oil.

[0227] Another fatty substance which can be present in the oily phase can, for example, be:- a fatty acid such as fatty acids comprising from 8 to 30 carbon atoms, such as stearic acid, lauric acid, palmitic acid or oleic acid; preferably C12-C22higher fatty acids, such as oleic acid, linoleic acid or linolenic acid;- a wax chosen from waxes such as lanolin, beeswax, carnauba or candelilla wax, paraffin waxes, lignite waxes, microcrystalline waxes, ceresin or ozokerite, or synthetic waxes, such as polyethylene waxes or Fischer-Tropsch waxes;- a gum chosen from silicone gums (dimethiconol),- a pasty compound, such as polymeric or non-polymeric silicone compounds, esters of an oligomeric glycerol, arachidyl propionate, fatty acid triglycerides and derivatives thereof,- and mixtures thereof.

[0228] Preferentially, the overall fatty phase, including all the lipophilic substances of the composition capable of being solubilized in this same phase, including the lipophilic screening agents, represents from 5% to 95% by weight and preferentially from 10% to 80% by weight, relative to the total weight of the composition.Aqueous phase

[0229] The composition in accordance with the invention can comprise at least one aqueous phase.

[0230] The aqueous phase contains water and optionally other water-soluble or water-miscible organic solvents.

[0231] An aqueous phase which is suitable for the invention can comprise, for example, a water chosen from a natural spring water, such as water from La Roche-Posay, water from Vittel, water from Saint-Gervais Mont-Blanc or waters from Vichy, or a floral water.

[0232] The water-soluble or water-miscible solvents which are suitable for the invention comprise C1-C4monoalcohols and polyols as described above, and also diols, such as ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, hexylene glycol, diethylene glycol, dipropylene glycol, 2-ethoxyethanol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether, and mixtures thereof.

[0233] According to a specific form of the invention, the overall aqueous phase, including all the hydrophilic substances of the composition capable of being solubilized in this same phase, represents from 5% to 95% by weight and preferentially from 10% to 80% by weight, relative to the total weight of the composition.

[0234] According to a particular embodiment, the pH of the composition in accordance with the invention is between 6.5 and 8. Preferably, the pH of the composition in accordance with the invention is between 6.8 and 7.7. Even more preferentially, the pH of the composition in accordance with the invention is between 7 and 7.6.

[0235] The pH of the composition in accordance with the invention can be measured using a Mettler Toledo MPC227, SevenEasy pH or SevenGo SG2 pH meter at room temperature (25°C) and atmospheric pressure.Cosmetic active ingredients

[0236] The composition of the present invention may comprise at least one cosmetic active agent.

[0237] As examples of cosmetic active agents, mention may be made of moisturizing agents such as protein hydrolysates, polyglycerin-3; natural extracts; vitamins and derivatives (in particular esters) thereof, and also mixtures thereof; urea; caffeine; salicylic acid and derivatives thereof; α-hydroxy acids and derivatives thereof; retinoids; extracts of algae, fungi, plants, yeasts and bacteria; enzymes; tensioning agents; agents acting on the microcirculation, and mixtures thereof.

[0238] A person skilled in the art can readily adjust the amount of cosmetic active principle according to the intended use of the composition according to the present invention.Additional adjuvants or additives

[0239] The composition of the present invention may also comprise conventional cosmetic adjuvants or additives, for example fragrances, chelating agents (for example, tetrasodium glutamate diacetate and disodium EDTA), preservatives (for example, chlorphenesin and phenoxyethanol) and bactericides, surfactants, additional co-emulsifiers and / or thickeners (such as an acryloyldimethyltaurate homopolymer or an acrylamide / sodium acryloyldimethyltaurate copolymer, an acrylates / C10-C30alkyl acrylate crosspolymer copolymer, hydroxypropylguar), pH regulators (for example triethanolamine, citric acid and sodium hydroxide), fillers (for example aluminum starch octenylsuccinate and polymethylsilsesquioxane) and mixtures thereof.

[0240] A person skilled in the art can select the amount of additional adjuvants or additives in such a way as to not be detrimental to the final use of the composition according to the present invention.Examples

[0241] The examples that follow serve to illustrate the invention without, however, being limiting in nature. In these examples, the amounts of the ingredients in the compositions are given as % by weight of raw materials or of active materials, relative to the total weight of the composition.Preparation method of the compositions

[0242] Add the raw materials of phase A1 and heat to 70°C.Once the mixture is homogeneous, turn off the heating and add phase A2.Separately, add the raw materials of phase B and heat to 60°C.Once the mixture is homogeneous, transfer phase B into phase A with stirring.Begin cooling.Once the mixture has reached 30°C, incorporate phase C and then phase D.Continue stirring until a homogeneous mixture is obtained.Protocol for in vitro evaluation of sand adhesion

[0243] Place 2 kg of sand in a tank.Weigh the PMMA plate without product; the mass obtained is recorded as M1.Each composition is applied to 5 rough PMMA plates (reference HD6 from Helioscreen), in the form of a uniform and even deposit in an amount of 1.3 mg / cm2.Wait 5 minutes, then weigh the plates. The average mass obtained is recorded as M2.Next, lay the plates in the tank of sand with a 2 kg weight on top and leave for 30 seconds.Remove the plates, then place them at a 45° inclination before tapping them lightly 3 times to make the excess sand fall off and to retain only what is actually stuck.Next, weigh the plates. The average mass obtained is recorded as M3.The average amount of sand which has remained stuck to the plate is then calculated according to the following formula: Ms = M3-M2.The higher the value obtained, the higher the sand adhesion of the composition.Hydration Evaluation Protocol

[0244] Experimental Conditions: The compositions to be evaluated are applied in vivo. The application was randomized: randomization of 4 zones (3 treated, 1 control) on two volunteers.

[0245] Treated Zone: Application of the product using a single-use finger cot on the treated area (on a surface of 16 cm², or 4x4 cm), at a rate of 2 mg / cm², by massage until the product is evenly distributed.

[0246] Control Zone: An area of approximately 16 cm² (or 4x4 cm), delimited in the same way as for the treated zone but having received no product.Evaluation of the Moisturizing Effect - Principle

[0247] The hydration level of the upper layers of the skin was quantitatively assessed by capacitance measurements provided by the Corneometer (corneometric index), at different experimental times, notably immediately after application (T0H) and 1 hour after application (T1H). The moisturizing effect of the product was evaluated by statistical comparison of the corneometric index obtained on the experimental zones (treated and control) at each experimental time point. The measurement was taken on the randomized square at T0H then at T1H.Measuring Instrument:

[0248] Measurements were performed with the Corneometer CM 825 PC® (Courage & Khazaka) which operates at an average frequency of 1 MHz and is equipped with a 0.64 cm² probe composed of 75 μm electrodes (the probe is wiped between each measurement using a cellulose wadding tissue). The capacitance of the system, represented by the electrodes and the upper layers of the skin, being influenced by changes in the dielectric constant of the skin surface, when the hydration level of the stratum corneum varies, the dielectric properties of this medium are modified and consequently the capacitance of the system is modified.Experimental Conditions:

[0249] The environmental conditions imposed on the volunteers, at least 20 minutes before each measurement, are as follows:Controlled temperature: T° = 21.5 °C ± 1.5 (from 20 to 23 °C)Controlled relative humidity: RH = 50 % ± 10 (from 40 to 60 %)

[0250] During the measurements, the volunteers are comfortably seated, with their forearm resting on a flat, rigid surface.

[0251] All measurements are performed blind (by a technician different from the person applying the product).

[0252] The forearms were previously wiped 3 times (downwards) with absorbent paper before each measurement.Viscosity Evaluation Protocol

[0253] The viscosity evaluation is carried out using a Rheomat RM200 viscometer (Lamy company) at 25°C. We use an MsR-2 spindle, due to the fluid texture of the formula. We calibrate the viscometer, then introduce the spindle into the product and let it rotate at 200 revolutions per minute for 10 minutes. We take the viscosity measurement at 10 minutes.

[0254] Stability Evaluation Protocol for the Compositions of the Invention

[0255] Each composition is subjected to two separate stability tests:First, each composition is placed in an oven at 55°C for one week in 100 ml bottles. After one week, we take the compositions out and analyze their appearance macroscopically and microscopically.Second, each composition is placed in an oven at 45°C for one month in 100 ml bottles. After one month, we take the compositions out and analyze their appearance macroscopically and microscopically.Compositions 1 to 4

[0256] The following compositions are prepared (amounts of raw materials).PhaseComposition1(invention)2(invention)3(invention)4(comparative)A1BEHENYL ALCOHOL (and) GLYCERYL STEARATE (and) DISODIUM ETHYLENE DICOCAMIDE PEG-15 DISULFATE (and) GLYCERYL STEARATE CITRATE(CERALUTION H from SASOL)2.502.502.502.50A1BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE(TINOSORB S from BASF)4.004.004.004.00A1BUTYL METHOXYDIBENZOYLMETHANE(PARSOL 1789 from DSM NUTRITIONAL PRODUCTS)4.004.004.004.00A1C12-15 ALKYL BENZOATE4.504.504.504.50A1CETYL ALCOHOL0.500.500.500.50A1DICAPRYLYL CARBONATE2.002.002.002.00A1ETHYLHEXYL TRIAZONE(UVINUL T150 from BASF)4.004.004.004.00A1ISOPROPYL MYRISTATE10.0010.0010.0010.00A1POLY C10-C30 ALKYL ACRYLATE(TEGO SP 13-1 from EVONIK)0.500.500.500.50A2VITAMIN(S)0.250.250.250.25A2FRAGRANCE0.600.600.600.60A2ACTIVE AGENT(S)0.100.100.100.10BWATER / AQUA46.1041.1048.1056.10BPRESERVATIVE(S)0.500.500.500.50BGLYCERIN4.004.004.004.00BPHENYLBENZIMIDAZOLE SULFONIC ACID(EUSOLEX 232 from MERCK)2.002.002.002.00BSODIUM STEAROYL GLUTAMATE(ACYLGLUTAMATE HS 11 from AJINOMOTO)0.150.150.150.15BTRIETHANOLAMINE1.701.701.701.70BCHELATING AGENT(S)0.300.300.300.30CACRYLATES COPOLYMER(CARBOPOL AQUA SF-1 POLYMER from LUBRIZOL)2.002.002.002.00DDENAT. ALCOHOL10.0015.008.00-DFILLER(S)0.300.300.300.30Results obtained

[0257] The results obtained are as follows:Composition1 (invention)2 (invention)3 (invention)4 (comparative)M29.699.5010.009.37M310.129.8210.419.87Ms = M3 – M20.430.320.410.50Standard deviation0.020.060.030.02

[0258] These results show that compositions 1 to 3 in accordance with the invention which contain at least 8% by weight of ethanol have a significantly reduced sand adhesion compared with comparative composition 4 which does not contain ethanol.Compositions 5 and 6

[0259] The following compositions are prepared (amounts of raw materials).PhaseComposition5(invention)6(invention)A1BEHENYL ALCOHOL (and) GLYCERYL STEARATE (and) DISODIUM ETHYLENE DICOCAMIDE PEG-15 DISULFATE (and) GLYCERYL STEARATE CITRATE(CERALUTION H from SASOL)2,502,50A1BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE(TINOSORB S from BASF)4,004,00A1BUTYL METHOXYDIBENZOYLMETHANE(PARSOL 1789 from DSM NUTRITIONAL PRODUCTS)4,004,00A1C12-15 ALKYL BENZOATE4,504,50A1CETYL ALCOHOL0,500,50A1DICAPRYLYL CARBONATE2,002,00A1ETHYLHEXYL TRIAZONE(UVINUL T150 from BASF)4,004,00A1ISOPROPYL MYRISTATE10,0010,00A1POLY C10-C30 ALKYL ACRYLATE(TEGO SP 13-1 from EVONIK)0,50-A1SODIUM POLYACRYLATE(COSMEDIA SP from BASF-0,50A2VITAMIN(S)0,250,25BACTIVE AGENT(S)0,100,10BWATER / AQUA47,0047,00BPRESERVATIVE(S)0,500,50BGLYCERIN4,004,00BSODIUM STEAROYL GLUTAMATE(ACYLGLUTAMATE HS 11 from AJINOMOTO)0,150,15BPHENYLBENZIMIDAZOLE SULFONIC ACID(EUSOLEX 232 from MERCK)2,002,00BTRIETHANOLAMINE1,701,70BCHELATING AGENT(S)0,300,30CACRYLATES COPOLYMER(CARBOPOL AQUA SF-1 POLYMER from LUBRIZOL)2,002,00DALCOHOL DENAT.10,0010,00Results obtained

[0260] The results obtained are as follows:CompositionBarre skin (reference)5 (invention)6 (invention)Corneometric Measurement at T0244562Corneometric Measurement at T1H315549% hydratation8 %11 %- 12 %

[0261] These results show that composition 5, according to the invention, which contains a semi-crystalline polymer containing at least one alkyl acrylate chain (TEGO SP 13-1 from EVONIK), allows better skin hydration, immediately after application and over time, than composition 6, according to the invention, in which the semi-crystalline polymer containing at least one alkyl acrylate chain has been replaced by a sodium polyacrylate (Cosmedia SP from BASF).Compositions 7 to 9

[0262] The following compositions are prepared (amounts of raw materials).PhaseComposition7(invention)8(invention)9(invention)A1BEHENYL ALCOHOL (and) GLYCERYL STEARATE (and) DISODIUM ETHYLENE DICOCAMIDE PEG-15 DISULFATE (and) GLYCERYL STEARATE CITRATE(CERALUTION H from SASOL)2,502,502,50A1BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE(TINOSORB S from BASF)4,004,004,00A1BUTYL METHOXYDIBENZOYLMETHANE(PARSOL 1789 from DSM NUTRITIONAL PRODUCTS)4,004,004,00A1C12-15 ALKYL BENZOATE4,504,504,50A1CETYL ALCOHOL0,500,500,50A1DICAPRYLYL CARBONATE2,002,002,00A1ETHYLHEXYL TRIAZONE(UVINUL T150 from BASF)4,004,004,00A1ISOPROPYL MYRISTATE10,0010,0010,00A1POLY C10-C30 ALKYL ACRYLATE(TEGO SP 13-1 from EVONIK)0,500,500,50A2VITAMIN(S)0,250,250,25BACTIVE AGENT(S)0,100,100,10BWATER / AQUA47,0047,1547,15BPRESERVATIVE(S)0,500,500,50BGLYCERIN4,004,004,00BINULIN LAURYL CARBAMATE(INUTEC SL1 from CREACHEM)-0,15BPHENYLBENZIMIDAZOLE SULFONIC ACID(EUSOLEX 232 from MERCK)2,002,002,00BSODIUM STEAROYL GLUTAMATE(ACYLGLUTAMATE HS 11 from AJINOMOTO)0,15--BTRIETHANOLAMINE1,701,701,70BCHELATING AGENT(S)0,300,300,30CACRYLATES COPOLYMER(CARBOPOL AQUA SF-1 POLYMER from LUBRIZOL)2,002,002,00DALCOHOL DENAT.10,0010,0010,00Results obtained

[0263] The results obtained are as follows:Composition7 (invention)8 (invention)9 (invention)Initial macroscopic appearance at 25 °CFluid, shinyFluid, shinyFluid, shinyViscosity (mPa.s) at 10 minutes25 mPa.s26 mPa.s26 mPa.sStability after 1 week at 55 °CMacroscopic: Absence of water sediment, homogeneous and fluid formula.Microscopic: Fine, regular, tight emulsion, sharp edges. Isotropic.Macroscopic: Water sediment >1cm and oil droplets on the surface.Microscopic: Coarse, irregular, loose emulsion, loose and blurry edges. Isotropic.Macroscopic: Water sediment >1cm.Microscopic: Medium, irregular, loose emulsion, loose and blurry edges. Isotropic.Stability after 1 month at 45 °CMacroscopic: Absence of water sediment, homogeneous and fluid formula.Microscopic: Fine, regular, tight emulsion, sharp edges. Isotropic.Macroscopic: Water sediment >1cm and oil droplets on the surface.Microscopic: Coarse, irregular, loose emulsion, loose and blurry edges. Isotropic.Macroscopic: Water sediment >1cm.Microscopic: Medium, irregular, loose emulsion, loose and blurry edges. Isotropic.

[0264] These results show that composition 7, in accordance with the invention, which contains a surfactant chosen from among amino acids modified by at least one C8-C30 hydrocarbon chain and their salts (ACYLGLUTAMATE HS 11 from AJINOMOTO), exhibits greater stability than composition 8, in accordance with the invention, in which this surfactant has been replaced by another surfactant, inulin lauryl carbamate (INUTEC SL1 from CREACHEM), and than composition 9, in accordance with the invention, which does not contain such a surfactant.

Claims

A composition, in particular a cosmetic or dermatological composition, comprising:(a) at least one lipophilic organic UV-screening agent;(b) at least one gemini surfactant chosen from the compounds of formula (IV), and the stereoisomers thereof:(IV)wherein:R1and R3denote, independently of one another, an alkyl radical having from 1 to 25 carbon atoms;R2denotes a spacer constituted of a linear or branched alkylene chain having from 1 to 12 carbon atoms;X and Y denote, independently of one another, a –(C2H4O)a-(C3H6O)bZ group where:- Z denotes a hydrogen atom or a –CH2-COOM, -SO3M, -P(O)(OM)2, –C2H4-SO3M, –C3H6-SO3M or –CH2(CHOH)4CH2OH radical, where M represents H or an alkali metal ion or alkaline-earth metal ion or ammonium ion or alkanolammonium ion,- a ranges from 0 to 15,- b ranges from 0 to 10, and- the sum of a + b ranges from 1 to 25; and- n ranges from 1 to 10; and(c) at least one C1-C4monoalcohol in an amount at least equal to 8% by weight of the total weight of the composition ;the composition being free of liquid lipophilic organic UV-screening agents.A composition, in particular a cosmetic or dermatological composition, comprising:(a) at least one lipophilic organic UV-screening agent;(b) at least one gemini surfactant chosen from the compounds of formula (IV), and the stereoisomers thereof:(IV)wherein:R1and R3denote, independently of one another, an alkyl radical having from 1 to 25 carbon atoms;R2denotes a spacer constituted of a linear or branched alkylene chain having from 1 to 12 carbon atoms;X and Y denote, independently of one another, a –(C2H4O)a-(C3H6O)bZ group where:- Z denotes a hydrogen atom or a –CH2-COOM, -SO3M, -P(O)(OM)2, –C2H4-SO3M, –C3H6-SO3M or –CH2(CHOH)4CH2OH radical, where M represents H or an alkali metal ion or alkaline-earth metal ion or ammonium ion or alkanolammonium ion,- a ranges from 0 to 15,- b ranges from 0 to 10, and- the sum of a + b ranges from 1 to 25; and- n ranges from 1 to 10; and(c) at least one C1-C4monoalcohol in an amount at least equal to 8% by weight of the total weight of the composition ;wherein the lipophilic organic UV-screening agent(s) present in the composition are solids.The composition as claimed in one of claims 1 and 2, wherein the lipophilic organic UV-screening agent(s) are chosen from butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, 4-methylbenzylidene camphor, drometrizole trisiloxane, phenylene bis-diphenyltriazine, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, diethylhexyl butamido triazone, preferably butyl methoxydibenzoylmethane, diethylamino hydroxybenzoyl hexyl benzoate, drometrizole trisiloxane, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, and even more preferentially butyl methoxydibenzoylmethane, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone.The composition as claimed in any one of claims 1 to 3 comprising at least one solid lipophilic organic UVA screening agent, preferably chosen from butyl methoxydibenzoylmethane and diethylamino hydroxybenzoyl hexyl benzoate, and at least one solid lipophilic organic UVB screening agent, preferably chosen from ethylhexyl triazone and diethylhexyl butamido triazone.The composition as claimed in any one of claims 1 to 4 comprising at least one solid lipophilic organic hybrid UV-screening agent capable of absorbing UVA and UVB rays, preferably chosen from drometrizole trisiloxane and bis-ethylhexyloxyphenol methoxyphenyl triazine.The composition as claimed in any one of claims 1 to 5, wherein the amount of lipophilic organic UV-screening agents is greater than or equal to 10% by weight, preferably greater than or equal to 25% by weight, notably greater than or equal to 55% by weight, and even more preferentially greater than or equal to 80% by weight of the total weight of lipophilic organic screening agents present in the composition.The composition as claimed in any one of claims 1 to 6, comprising at least one lipophilic organic UV-screening agent other than butyl methoxydibenzoylmethane.The composition as claimed in any one of claims 1 to 7, comprising at least one hydrophilic organic UV-screening agent.The composition as claimed in any one of claims 1 to 8, wherein, for the gemini surfactant of formula (IV), each of the R1-CO- and R3-CO- groups comprises from 8 to 20 carbon atoms.The composition as claimed in any one of claims 1 to 9, wherein, for the gemini surfactant of formula (IV), each of the R1-CO- and R3-CO- groups denotes a coconut fatty acid residue.The composition as claimed in any one of claims 1 to 10, wherein, for the gemini surfactant of formula (IV), for each of the X and Y radicals, the sum of a and b has a mean value ranging from 10 to 20.The composition as claimed in any one of claims 1 to 11, wherein, for the gemini surfactant of formula (IV), Z is the –SO3M group, where M is an alkali metal ion such as a sodium ion.The composition as claimed in any one of claims 1 to 12, wherein, for the gemini surfactant of formula (IV), n is equal to 1.The composition as claimed in any one of claims 1 to 13, wherein the surfactant of formula (IV) has the following structure:The composition as claimed in any one of claims 1 to 14, wherein the gemini surfactant is mixed with (a) a glycerol ester of a C6-C22fatty acid, (b) a glycerol diester of a C6-C22fatty acid and of citric acid, and (c) a C10-C30fatty alcohol.The composition as claimed in any one of claims 1 to 15, wherein the C1-C4monoalcohol is ethanol.The composition as claimed in any one of claims 1 to 16, wherein the C1-C4monoalcohol is in an amount at least equal to 10% by weight, preferably between 10% by weight and 40% by weight relative to the total weight of the composition.The composition as claimed in any one of claims 1 to 17, in the form of an emulsion, preferably in the form of an oil-in-water emulsion.

Images